

# Covalon Technologies Ltd. to Showcase Innovative Vascular Access Solutions at the Annual Association of Pediatric Hematology/Oncology Nurses Conference

2024-09-11

Visit Covalon at booth 406 to discover the latest in compassionate vascular access solutions.

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) Annual 2024 Conference. The conference, taking place in Salt Lake City, Utah from September 11 to 13, is a premier event for pediatric hematology/oncology nursing professionals involved in patient care, education, case management, and research.

(Graphic: Business Wire)

"Our silicone adhesive-based IV dressings highlight our

commitment to patient care and comfort. The gentle, flexible silicone adapts like a second skin, offering pediatric patients more freedom while reducing the fear of painful removal," said Ron Hebert, Senior Vice President of Growth at Covalon. "This conference offers an excellent opportunity to engage with top pediatric healthcare providers dedicated to bringing the latest advancements to their patients through our innovative solutions."

Attendees are encouraged to visit Covalon at booth #406 to explore our range of vascular access solutions and discover why leading hospitals trust our products. Covalon representatives will be available to discuss these innovations and answer any questions.

Covalon's patented vascular access products include:

- **VALGuard®** - a transparent line guard designed to protect IV line connections and hubs from external contaminants, including body fluids and other secretions.
- **SurgiClear®** - a dual antimicrobial clear silicone adhesive dressing with Chlorhexidine and Silver used to cover and protect wound sites and wound closure devices.
- **IV Clear®** - a dual antimicrobial (Chlorhexidine and Silver) clear IV securement dressing that provides antimicrobial protection throughout the entire dressing surface area.
- **CovaClear® IV** - a soft silicone adhesive clear IV dressing that helps protect insertion sites from external contaminants. Suitable for patients who either don't require, or cannot tolerate, antimicrobials.

## Scheduling Appointments and Additional Information

To book an appointment with a Covalon representative, please email Ron Hebert, SVP Growth, Covalon Technologies Ltd., at [rhebert@covalon.com](mailto:rhebert@covalon.com).

## Conference Details

- Dates: September 11 – 13, 2024
- Location: Salt Lake Marriott Downtown at City Creek (75 S W Temple St, Salt Lake City, UT 84101, United States)
- Registration: <https://www.aphon.org/2024-annual-conference>

For healthcare providers unable to attend the conference, Covalon encourages you to visit [www.covalon.com](http://www.covalon.com) or follow the company on **LinkedIn**, **Facebook**, or **Instagram** to learn more about its solutions.

## About Covalon

Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions for advanced wound care, infection control, and medical device coatings. Through a strong portfolio of patented technologies and solutions, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at [www.covalon.com](http://www.covalon.com).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2023, which is available on the Company's profile at [www.sedarplus.ca](http://www.sedarplus.ca), any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

To learn more about Covalon, please contact:

Investor Relations, Covalon Technologies Ltd.

Email: [investors@covalon.com](mailto:investors@covalon.com)

Website: <https://covalon.com/>

Source: Covalon Technologies Ltd.